

ELECTRONIC INFORMATION DISCLOSURE STATEMENT

Electronic Version v18 Stylesheet Version v18.0

> Title of Invention

ANGIOGENESIS-INHIBITORY TRIPEPTIDES, COMPOSITIONS AND THEIR METHODS OF USE

Application Number:

10/074389

Confirmation Number:

5572

First Named Applicant:

MARK SCIALDONE

Attorney Docket Number: CL1723 US NA

Search string:

(5092885 or 5112946 or 5192744 or

5202352).pn.

RECEIVED.

JUL 2 1 7003

TECH CENTER 1600/2000

US Patent Documents

Note: Applicant is not required to submit a paper copy of cited US Patent Documents

init	Cite.No.	Patent No.	Date	Patentee	Kind	Class	Subclass
Pu		5092885	1992-03-03	YAMADA ET AL		623	1/
the		5112946	1992-05-12	MAIONE		530	324
dh		5192744	1993-03-09	BOUCK ET AL.		514	8
12/2		5202352	1993-04-13	OKADA ET AL]	574	475

Signature

Examiner Name	Date
1 st Avy	3/4/04

PTO/SB/08b(05-03)
Approved for use through 04/30/2003. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Vene	N. C.					$\overline{}$	
Substitute for for				Complete if Known			
				Application Number	10/074389		
INFORMATION DISCLOSURE				Filing Date	February 12, 2002		
STATEMENT BY APPLICANT			CANT	First Named Inventor	Shaker A. Mousa Et. Al.		
(Use as many sheets as necessary)				Art Unit	1643	-	
				Examiner Name			
Sheet	1	of	2	Attorney Docket Number	CL1723 US NA	/	

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
M		Mousa, S. A., Angiogenesis Inhibitors and Stimulators: Potential Therapeutic Implications, Landes Bioscience, Georgetown, TX; Chapter 1, (2000)	
Mu		Breier et al., Trends in Cell Biology, 6: 454-456 (1996)	
Mu		Folkman, Nature Medicine 1: 27-31 (1995)	
(Ma)	!	Risau, Nature 386: 671-674 (1997)	
100		Blood et al., Bioch. Biophys. Acta. 1032:89-118 (1990)	
11.1		Folkman et al., Science 235: 442-447 (1987)	
Mu		Moses et al., Science 248: 1408-1410 (1990)	
Mu Mu Mu Mu		Folkman et al., Cancer Biology 3: 89-96 (1992)	
10		Han et al. J. Biol. Chem., 272:20395-20401 (1997)	
M		Shahan et al. Connective Tissue Res. 40: 221-232 (1999)	
Examiner		Date Considered 3/11/04	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO This collection of information. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including to processing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08b(05-03)
Approved for use through 04/30/2003. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE work Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number. Complete if Known for form 1449B/PTO Application Number 10/074389 INFORMATION DISCLOSURE February 12, 2002 Filing Date First Named Inventor Shaker A. Mousa Et. Al.

Art Unit

1643

STATEMENT BY APPLICANT

(Use as many sheets as necessary)

1	(Use as many sneets a	s necessary,	Examiner Name		
Sheet	2	of	2	Attorney Docket Number	CL1723 US NA

		NON PATENT LITERATURE DOCUMENTS	_T —
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
		Shahan et al., Cancer Res., 59: 4584-4590 (1999)	
Me			
/4.		Shahan et al., J. Biol. Chem. 275: 4796-4802 (2000)	
Mu			. └
Me Me		Pasco et al., Cancer Res. 60: 467-473 (2000)	
$\int P/U$		Maeshima et al., J. Biol. Chem. 275: 21340-21348 (2000)	-
M		Maeshima et al., J. Biol. Chem. 270. 21010 21019 (2007)	
P lu			
			L
	,		<u></u>
	ļ		
	1		
Examiner Signature		Date Considered 3/11/04	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.